• Explore /
  • Poster
  • / Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.

Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.

Abstract Poster

Authors

Kohei Shitara

Kohei Shitara

Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Kohei Shitara , Rupesh Pophale , Maria Matsangou , Jung Wook Park , Mok Oh , Pranob P. Bhattacharya , Radhika Ranganath

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03504397 and NCT03653507

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 372)

DOI

10.1200/JCO.2024.42.3_suppl.372

Abstract #

372

Poster Bd #

H14

Abstract Disclosures

Similar Posters

First Author: Kohei Shitara

First Author: Kohei Shitara

First Author: Manish A. Shah

First Author: Manish A. Shah